Lv0
0 积分 2022-05-05 加入
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
9天前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2个月前
已完结
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
2个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2个月前
已完结
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
2个月前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
2个月前
已完结
Cancer incidence and mortality in China, 2022
5个月前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
6个月前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
6个月前
已完结
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
